Drug profile · INN
valsartan
DILART
valsartan (DILART) is a type-1 angiotensin ii receptor antagonist. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — valsartan
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 2
- Programs
- 6
- Data quality
- 0.89
Quick answer
valsartan (DILART) is a type-1 angiotensin ii receptor antagonist. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Type-1 angiotensin II receptor antagonist
Primary target: Type-1 angiotensin II receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| TGA | approved | — |
| NMPA | clinical trials | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is valsartan?
valsartan (DILART) is a type-1 angiotensin ii receptor antagonist. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for valsartan?
DILART is a marketed brand name for valsartan. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of valsartan?
valsartan has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.